64
Participants
Start Date
May 31, 2010
Primary Completion Date
August 31, 2016
Study Completion Date
August 31, 2016
Ipilimumab
Induction Phase: 10 mg/kg by vein (IV) over approximately 90 minutes on Day 1 only repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose repeated every 12 weeks.
Temozolomide
Induction Phase, 200 mg/m\^2 by mouth (PO) on Days 1 to 4, repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose delivered on Days 1 to 5, repeated every 4 weeks.
University of Texas MD Anderson Cancer Center, Houston
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
M.D. Anderson Cancer Center
OTHER